Interleukin-12 (IL 12)

A heterodimeric cytokine that plays a role in innate and adaptive immune responses. Interleukin-12 is a 70 kDa protein that is composed of covalently linked 40 kDa and 35 kDa subunits. It is produced by DENDRITIC CELLS; MACROPHAGES and a variety of other immune cells and plays a role in the stimulation of INTERFERON-GAMMA production by T-LYMPHOCYTES and NATURAL KILLER CELLS.

Also Known As:

Networked: 6553 relevant articles (534 outcomes, 884 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Egilmez, Nejat K: 20 articles (05/2014 - 05/2002)
2.	Hunter, Christopher A: 19 articles (11/2015 - 04/2002)
3.	Sher, Alan: 18 articles (09/2013 - 06/2002)
4.	Casanova, Jean-Laurent: 17 articles (09/2015 - 02/2002)
5.	Akira, Shizuo: 17 articles (01/2013 - 01/2002)
6.	Di Carlo, Emma: 17 articles (10/2010 - 07/2002)
7.	Smyth, Mark J: 16 articles (07/2015 - 02/2002)
8.	Li, Shulin: 16 articles (03/2015 - 05/2002)
9.	Takeda, K: 16 articles (08/2003 - 02/2000)
10.	Cua, Daniel J: 15 articles (07/2015 - 02/2003)

Related Diseases

1.	Neoplasms (Cancer) 02/01/2001 - "The combination of IL-12 cytokine therapy with GCV treatment was the most efficacious approach, with significantly greater inhibition of tumor growth than IL-12 or TK + GCV alone. " 07/01/1997 - "In summary, gene therapy strategies for cancer using adenoviral vectors containing IL-12 are highly effective with no significant toxicity in mice." 05/15/2014 - "Combinatorial treatment with RT and the immunomodulatory cytokine IL-12 resulted in complete remission of cancer in 100% of cases compared to a cure rate of only 12% with RT alone. " 08/01/2010 - "Intratumoral IL-12 electrogene therapy has been proved to be very effective in local tumor control, having also a systemic effect. " 11/01/2009 - "Intratumoral IL-12 EGT resulted in over 90% complete response rate of the treated tumors with 60% of cured mice being resistant to challenge with SA-1 tumor cells. "
2.	Infection 04/01/2006 - "The results showed that the best protection against challenge infection was obtained by ALM + IL-12 followed by ALM + BCG. " 04/01/2002 - "Thus, while IL-12 p70 stimulation of IFN-gamma production may be important for bacteriostasis, IL-12 p70 is not necessary for appropriate development of LVS-immune T cells that are capable of controlling intracellular bacterial growth and for clearance of primary or secondary LVS infection. " 01/15/1999 - "Local treatment with IL-12 inoculated into the parasitized lesion at 4 wk of infection induced a marked increase in IFN-gamma production but did not result in a significant reduction in numbers of parasite or promote more rapid healing. " 05/01/1994 - "Thus, IL-12 appears to play an important, but transitory, role in protection against acute infection with T. " 01/01/2014 - "A single chain grouper IL-12 (scgIL-12) construct linked by (G4S)3 was successfully expressed in baculovirus-insect cell system; its identity has been confirmed by LC/MS/MS. In addition, the biological activity of recombinant scgIL-12 (rscgIL-12) are demonstrated for its stimulation of PBL proliferation, chemotactic migration, induction of TNF-α gene expression and a plausible adjuvant effect of prolonged protection against parasite infection in fish. "
3.	Psoriasis (Pustulosis Palmaris et Plantaris) 02/01/2008 - "ABT-874, an interleukin 12/23 monoclonal antibody, was highly effective and well tolerated in the treatment of psoriasis. " 04/01/2009 - "New anti-IL-12/23 therapies offer another more specific option in the management of chronic plaque psoriasis. " 12/01/2008 - "These promising results strongly confirm the central role of IL-12/23 in psoriasis and its importance as a therapeutic target." 02/01/2008 - "Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial." 06/01/2012 - "We describe the case of a patient who experienced a flare of pustular psoriasis after initiating anti-interleukin-12/23 therapy, which subsequently improved following discontinuation of the drug."
4.	Neoplasm Metastasis (Metastasis) 11/01/2002 - "We have therefore, evaluated the therapeutic efficacy of dendritic cells (DCs) engineered to express IL-12 in a liver metastasis model. " 07/01/2000 - "We further demonstrate that the innate and the adaptive antitumoral immune responses were synergistic, as animals bearing hepatic as well as multiple pulmonary metastases were quantitatively cured of their diseases after IL-12 gene therapy + anti-4-1BB combination treatment. " 05/01/2012 - "Although delivery of IL-12 alone also inhibited the number of CRC liver metastasis observed, further study of the change in hepatic metastasis volume demonstrated no significant differences between the groups treated with CS-TPP or IL-12 alone. " 03/15/2006 - "In the protective and therapeutic studies of fusion cell vaccine, mice vaccinated with fusion/LacZ, fusion/IL-12, fusion/IL-18, or fusion/IL-12/IL-18 showed a significant decrease in liver metastasis and a significant increase in survival compared with mice given a mixture/LacZ, DCs/LacZ, or C1300/LacZ. " 01/01/2002 - "In this study, we examined the usefulness of local IL-12 administration into the portal system in the treatment of liver metastasis. "
5.	Melanoma (Melanoma, Malignant) 12/01/2002 - "Similarly, IL-12 seems to be beneficial in melanoma and has been used as a very potent adjuvant for eliciting immune responses to immunization. " 09/01/2011 - "Intratumoral administration of RdB/IL-12/IL-18 improved antitumor effects, as well as increased survival, in B16-F10 murine melanoma model. " 04/01/2011 - "We tested the efficacy of the inducible IL-12 vector in vivo in a murine melanoma model. " 05/15/2015 - "Thirty-three patients with metastatic melanoma were treated in a cell dose-escalation trial of autologous TILs transduced with a gene encoding a single-chain IL12 driven by a nuclear factor of the activated T cells promoter (NFAT.IL12). " 01/01/2010 - "EGT with IL-12 is in melanoma clinical trials and nsPEFs are used in models with B16F10 melanoma in vitro and in mice. "

Related Drugs and Biologics

1.	Cytokines
2.	Interleukin-12 (IL 12)
3.	Interleukin-2 (IL2)
4.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
5.	Interleukin-10 (Interleukin 10)
6.	Interleukins
7.	adjuvant P40 (P 40)
8.	Interferon-gamma (Interferon, gamma)
9.	Interleukin-23 (Interleukin 23)
10.	DNA (Deoxyribonucleic Acid)

Related Therapies and Procedures

1.	Immunotherapy
2.	Heterologous Transplantation (Xenotransplantation)
3.	Injections
4.	Oral Administration
5.	Drug Therapy (Chemotherapy)